Navigation Links
BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Date:9/4/2012

LYNBROOK, N.Y., Sept. 4, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the following two upcoming investor conferences in September:

  • Rodman & Renshaw 14th Annual Healthcare Conference
    Monday, September 10, 2012 at 11:40 am EDT
    New York, NY
  • ThinkEquity 9th Annual Growth Conference
    Thursday, September 13, 2012 at 9:30 am EDT
    New York, NY

The live webcasts of these presentations may be accessed under "Calendar of Events" in the Investor Relations section of the BioSpecifics' website at www.biospecifics.com. A replay of the webcasts will also be available on the Company's website following the presentations.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
4. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
5. Global E-Clinical Trial Technologies Industry
6. Antifungal Drugs: Technologies and Global Markets
7. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
8. Breast Cancer Diagnostic and Drug Technologies: Global Markets
9. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
10. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
11. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2019)... PRINCETON, N.J. (PRWEB) , ... November 14, 2019 ... ... imaging services for clinical trials, announced today that it has reached a milestone ... efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... K-FISH, aimed to promote the quality of Korean seafood and enhance its global ... entitled, "K-Seafood Global Weeks" in many countries. These special events are currently ...
(Date:11/11/2019)... DELRAY BEACH, Fla. (PRWEB) , ... November 11, 2019 , ... ... standard in excellence for autologous biologics, is now representing two of the most respected ... , Based in Germany, Ameia Med is the leading developer of ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... November 15, 2019 , ... ... memory impairment, has announced the Best Memory Care Facilities in Amarillo, Texas. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:11/16/2019)... LAS VEGAS (PRWEB) , ... November 15, 2019 ... ... never seen before in the United States, access to cannabis via well-managed dispensaries ... medical marijuana industry. Wise Business Plans, industry-leading online provider of state-of-the-art, online, custom ...
(Date:11/15/2019)... ... November 15, 2019 , ... Anxiety is ... America (ADAA) puts the current figures of adults who suffer at 40 ... health issues manifest in many different ways, including Post Traumatic Stress Disorder (PTSD), ...
(Date:11/15/2019)... FULTON, Md. (PRWEB) , ... November 15, 2019 ... ... invests in and co-builds next-generation cybersecurity and data science companies with nation-state experienced ... the winner of its second-annual DataTribe Challenge is Code Dx Inc ., ...
(Date:11/14/2019)... ... November 14, 2019 , ... Inland Detox, Inc. is proud of and ... for former President Vicente Fox of Mexico. The Chefs Latinos Guanajuato Festival Gastronomico was ... was born and raised on Saturday, November 9, 2019. The event featured a total ...
Breaking Medicine News(10 mins):